Monday, July 15, 1996
One of the continuing challenges of drug research is to develop medications that are more precisely targeted against unhealthy cells. Such targeting kills two birds with one stone: enabling drugs to reach target cells and sparing patients some of the toxic side-effects that come when drugs damage healthy tissue as well.
Founded in 1990 by pediatric oncologist Arnold Glazier and fully operational since the fourth quarter of 1995, Drug Innovation and Design Inc. is focused on targeted therapeutics for cancer and viral diseases. One of DIAD's goals is to improve the effectiveness and reduce the toxicity of phosphorus drugs using prodrugs of phosphate or phosphonate-based antivirals.